Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 218

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study

Open access
Pautas, Cecile, Merabet, Fatiha, Thomas, Xavier, Raffoux, Emmanuel, Gardin, Claude, Corm, Selim, Bourhis, Jean-Henri, Reman, Oumedaly, Turlure, Pascal, Contentin, Nathalie, de Revel, Thierry, Rousselot, Philippe, Preudhomme, Claude, Bordessoule, Dominique, Fenaux, Pierre, Terré, Christine, Michallet, Mauricette, Dombret, Hervé, Chevret, Sylvie, Castaigne, Sylvie·2010·Journal of Clinical Oncology

Abstract

Purpose: In patients with acute myeloid leukemia (AML), induction chemotherapy is based on standard doses of anthracyclines and cytarabine. High doses of cytarabine have been reported as being too toxic for patients older than age 50 years, but few studies have evaluated intensified doses of anthracyclines. Patients and Methods: In this randomized Acute Leukemia French Association 9801 (ALFA-9801) study, high doses of daunorubicin (DNR; 80 mg/m 2/d × 3 days) or idarubicin (IDA4; 12 mg/m 2/d × 4 days) were compared with standard doses of idarubicin (IDA3; 12 mg/m 2/d × 3 days) for remission induction in patients age 50 to 70 years, with an event-free survival (EFS) end point. After two consolidation courses based on intermediate doses of cytarabine, patients in continuous remission were randomly assigned to receive or not receive maintenance therapy with recombinant interleukin-2 (rIL-2; 5 × 10 6 U/m 2× 5 days each month) for a total duration of 12 months. A total of 468 patients entered the study (median age, 60 years). Results: Overall complete remission rate was 77% with significant differences among the three randomization arms (83%, 78%, and 70% in the IDA3, IDA4, and DNR arms, respectively; P = .04). However, no significant differences were observed in relapse incidence, EFS, or overall survival among the three arms. In the 161 patients randomly assigned for maintenance therapy, no difference in outcome was observed between the rIL-2 and the no further treatment arms. Conclusion: Neither intensification of anthracycline doses nor maintenance with rIL-2 showed a significant impact on AML course, at least as scheduled in this trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2009.23.2652

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 218

Metadata

Authors
Pautas, C., Merabet, F., Thomas, X., Raffoux, E., Gardin, C., Corm, S., Bourhis, J.-H., Reman, O., Turlure, P., Contentin, N., de Revel, T., Rousselot, P., Preudhomme, C., Bordessoule, D., Fenaux, P., Terré, C., Michallet, M., Dombret, H., Chevret, S., & Castaigne, S.
Venue
Journal of Clinical Oncology
Published
2010-02-10
Volume
28
Issue
5
Pages
808-814
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2138571761
Cited by
218
References
2
FWCI
15.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study. https://app.cochat.ai/papers/10.1200/jco.2009.23.2652
The paper
Pautas, C., Merabet, F., Thomas, X., Raffoux, E., Gardin, C., Corm, S., Bourhis, J.-H., Reman, O., Turlure, P., Contentin, N., de Revel, T., Rousselot, P., Preudhomme, C., Bordessoule, D., Fenaux, P., Terré, C., Michallet, M., Dombret, H., Chevret, S., & Castaigne, S. (2010). Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.23.2652

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.